02162.HK
Keymed Biosciences Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 79.75
−0.99%Year over year
Reported trailing growth
- Revenue
- +314.5%
- EBITDA
- +28.8%
- EBIT
- +24.7%
- EPS
- +146.5%
- Free cash flow
- +1.8%
- Operating cash flow
- -7.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +91.1%
- EBITDA
- +14.8%
- EBIT
- +5.4%
- Net income
- +1.2%
- EPS
- +5.6%
- Free cash flow
- -4.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026